Endurant Capital Management LP Prothena Corp Public LTD CO Transaction History

Endurant Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$11.0 - $28.24 $1.67 Million - $4.29 Million	-151,820 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $1.12 Million - $1.55 Million	-110,953 Reduced 42.22%	151,820 $1.82 Million
Q3 2020 Nov 16, 2020	SELL	$9.93 - $13.47 $1.4 Million - $1.9 Million	-141,020 Reduced 34.92%	262,773 $2.63 Million
Q2 2020 Aug 14, 2020	BUY	$9.56 - $12.51 $1.41 Million - $1.85 Million	147,844 Added 57.76%	403,793 $4.22 Million
Q1 2020 May 15, 2020	BUY	$7.54 - $15.77 $1.1 Million - $2.3 Million	145,814 Added 132.4%	255,949 $2.74 Million
Q4 2019 Feb 14, 2020	BUY	$7.48 - $17.01 $177,485 - $403,613	23,728 Added 27.46%	110,135 $1.74 Million
Q3 2019 Nov 14, 2019	BUY	$6.89 - $10.45 $595,344 - $902,953	86,407 New	86,407 $677,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.